Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USB002 for Respiratory Distress in COVID-19
NCT04778059Phase 2Terminated
- Sponsor
- US Biotest, Inc.
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and respiratory distress syndrome (RDS) comparing USB002 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Jul 2021; status: terminated.
02
Drugs
angiotensin-(1-7)
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT04778059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778059.